FDA Approves Dato-DXd in HR+/HER2– Breast Cancer As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer.

BREAKING: The #FDA has approved datopotamab deruxtecan (Dato-DXd) for the treatment of patients with unresectable or metastatic HR+/HER2- breast cancer who have received prior systemic therapy. #bcsm

www.targetedonc.com/view/fda-app...

Group photos and our painted pottery masterpieces

Trading pipettes for paintbrushes and lab coats for aprons—our Christmas lab outing was all about pottery, painting, and pizza

Congrats to Myra Castel on passing her viva and obtaining her PhD! It was a pleasure to supervise the project funded through our @researchireland.bsky.social ACORN project. Thanks to the co-supervisory panel members @neilconlon.bsky.social, Dr Naomi Walsh, Prof John Crown @dcu-lsi.bsky.social

'We are invisible': Survey finds gaps in treatment of women with advanced breast cancer The survey carried out with Cancer Trials Ireland found one in five women cannot pay their monthly bills and 87% face mental illnesses

www.irishexaminer.com/news/arid-41...